Our finding that metformin users have a greater AD risk is consistent with that of animal studies, which have shown that metformin increases β-amyloid concentration by elevating the level of β-site amyloid precursor protein cleaving enzyme 1 or increases insoluble tau species in mice18,19. The gene discussed is MAPT; the disease is Alzheimer disease.